nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—ALB—acquired immunodeficiency syndrome	0.135	1	CbGaD
Imatinib—SLC47A1—Ritonavir—acquired immunodeficiency syndrome	0.0474	0.0805	CbGbCtD
Imatinib—ORM1—Saquinavir—acquired immunodeficiency syndrome	0.0177	0.0301	CbGbCtD
Imatinib—SLC22A1—Indinavir—acquired immunodeficiency syndrome	0.0145	0.0247	CbGbCtD
Imatinib—SLC22A1—Nelfinavir—acquired immunodeficiency syndrome	0.0141	0.0239	CbGbCtD
Imatinib—SLC22A2—Zidovudine—acquired immunodeficiency syndrome	0.014	0.0239	CbGbCtD
Imatinib—SLC22A1—Saquinavir—acquired immunodeficiency syndrome	0.0127	0.0217	CbGbCtD
Imatinib—ABCA3—alveolus of lung—acquired immunodeficiency syndrome	0.0125	0.165	CbGeAlD
Imatinib—ABCG2—Nelfinavir—acquired immunodeficiency syndrome	0.012	0.0203	CbGbCtD
Imatinib—SLC22A2—Lamivudine—acquired immunodeficiency syndrome	0.0109	0.0185	CbGbCtD
Imatinib—ABCG2—Ritonavir—acquired immunodeficiency syndrome	0.0108	0.0184	CbGbCtD
Imatinib—ABCG2—Saquinavir—acquired immunodeficiency syndrome	0.0108	0.0184	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Delavirdine—acquired immunodeficiency syndrome	0.0105	0.0179	CbGbCtD
Imatinib—CYP3A7—Delavirdine—acquired immunodeficiency syndrome	0.0105	0.0179	CbGbCtD
Imatinib—ABCG2—Zidovudine—acquired immunodeficiency syndrome	0.0104	0.0176	CbGbCtD
Imatinib—SLC22A1—Lamivudine—acquired immunodeficiency syndrome	0.00944	0.0161	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Indinavir—acquired immunodeficiency syndrome	0.0091	0.0155	CbGbCtD
Imatinib—CYP3A7—Indinavir—acquired immunodeficiency syndrome	0.0091	0.0155	CbGbCtD
Imatinib—CYP3A7—Nelfinavir—acquired immunodeficiency syndrome	0.00883	0.015	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Nelfinavir—acquired immunodeficiency syndrome	0.00883	0.015	CbGbCtD
Imatinib—CYP3A5—Nevirapine—acquired immunodeficiency syndrome	0.00874	0.0149	CbGbCtD
Imatinib—ABCG2—Lamivudine—acquired immunodeficiency syndrome	0.00802	0.0136	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Ritonavir—acquired immunodeficiency syndrome	0.00799	0.0136	CbGbCtD
Imatinib—CYP3A7—Saquinavir—acquired immunodeficiency syndrome	0.00799	0.0136	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Saquinavir—acquired immunodeficiency syndrome	0.00799	0.0136	CbGbCtD
Imatinib—CYP3A7—Ritonavir—acquired immunodeficiency syndrome	0.00799	0.0136	CbGbCtD
Imatinib—CYP3A5—Amprenavir—acquired immunodeficiency syndrome	0.00791	0.0134	CbGbCtD
Imatinib—CYP3A5—Delavirdine—acquired immunodeficiency syndrome	0.00791	0.0134	CbGbCtD
Imatinib—CYP2C19—Efavirenz—acquired immunodeficiency syndrome	0.0075	0.0128	CbGbCtD
Imatinib—ALB—Saquinavir—acquired immunodeficiency syndrome	0.00746	0.0127	CbGbCtD
Imatinib—ALB—Zidovudine—acquired immunodeficiency syndrome	0.00715	0.0122	CbGbCtD
Imatinib—CYP2C19—Lopinavir—acquired immunodeficiency syndrome	0.00705	0.012	CbGbCtD
Imatinib—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.00692	0.0118	CbGbCtD
Imatinib—CYP3A5—Indinavir—acquired immunodeficiency syndrome	0.00683	0.0116	CbGbCtD
Imatinib—CYP3A5—Nelfinavir—acquired immunodeficiency syndrome	0.00663	0.0113	CbGbCtD
Imatinib—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.00651	0.0111	CbGbCtD
Imatinib—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.00651	0.0111	CbGbCtD
Imatinib—CYP2C19—Amprenavir—acquired immunodeficiency syndrome	0.00638	0.0108	CbGbCtD
Imatinib—CYP2C19—Delavirdine—acquired immunodeficiency syndrome	0.00638	0.0108	CbGbCtD
Imatinib—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.00624	0.0106	CbGbCtD
Imatinib—CYP3A5—Saquinavir—acquired immunodeficiency syndrome	0.00599	0.0102	CbGbCtD
Imatinib—CYP3A5—Ritonavir—acquired immunodeficiency syndrome	0.00599	0.0102	CbGbCtD
Imatinib—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.00589	0.01	CbGbCtD
Imatinib—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.00586	0.00997	CbGbCtD
Imatinib—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.00586	0.00997	CbGbCtD
Imatinib—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0057	0.0097	CbGbCtD
Imatinib—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.00569	0.00968	CbGbCtD
Imatinib—CYP2C19—Indinavir—acquired immunodeficiency syndrome	0.00551	0.00936	CbGbCtD
Imatinib—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.00536	0.00912	CbGbCtD
Imatinib—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.00536	0.00912	CbGbCtD
Imatinib—CYP2C19—Nelfinavir—acquired immunodeficiency syndrome	0.00535	0.00909	CbGbCtD
Imatinib—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.0053	0.00902	CbGbCtD
Imatinib—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.0053	0.00902	CbGbCtD
Imatinib—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.00515	0.00875	CbGbCtD
Imatinib—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.00493	0.00839	CbGbCtD
Imatinib—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.00485	0.00825	CbGbCtD
Imatinib—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.00485	0.00825	CbGbCtD
Imatinib—CYP2C19—Saquinavir—acquired immunodeficiency syndrome	0.00483	0.00822	CbGbCtD
Imatinib—CYP2C19—Ritonavir—acquired immunodeficiency syndrome	0.00483	0.00822	CbGbCtD
Imatinib—CYP2C19—Zidovudine—acquired immunodeficiency syndrome	0.00463	0.00788	CbGbCtD
Imatinib—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.00458	0.00779	CbGbCtD
Imatinib—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.00446	0.00759	CbGbCtD
Imatinib—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.00444	0.00756	CbGbCtD
Imatinib—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.00444	0.00756	CbGbCtD
Imatinib—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.00431	0.00734	CbGbCtD
Imatinib—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.00419	0.00712	CbGbCtD
Imatinib—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.00406	0.00691	CbGbCtD
Imatinib—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.00402	0.00684	CbGbCtD
Imatinib—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.00402	0.00684	CbGbCtD
Imatinib—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.0039	0.00663	CbGbCtD
Imatinib—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.0039	0.00663	CbGbCtD
Imatinib—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.00385	0.00655	CbGbCtD
Imatinib—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.00374	0.00636	CbGbCtD
Imatinib—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.00367	0.00625	CbGbCtD
Imatinib—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.00367	0.00625	CbGbCtD
Imatinib—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00363	0.00617	CbGbCtD
Imatinib—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00341	0.0058	CbGbCtD
Imatinib—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00341	0.0058	CbGbCtD
Imatinib—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00308	0.00524	CbGbCtD
Imatinib—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00308	0.00524	CbGbCtD
Imatinib—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00289	0.00492	CbGbCtD
Imatinib—CA6—saliva—acquired immunodeficiency syndrome	0.00276	0.0362	CbGeAlD
Imatinib—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00266	0.00453	CbGbCtD
Imatinib—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00258	0.00439	CbGbCtD
Imatinib—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00234	0.00397	CbGbCtD
Imatinib—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00234	0.00397	CbGbCtD
Imatinib—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00224	0.00381	CbGbCtD
Imatinib—ORM1—saliva—acquired immunodeficiency syndrome	0.00147	0.0193	CbGeAlD
Imatinib—CA1—nerve—acquired immunodeficiency syndrome	0.000843	0.0111	CbGeAlD
Imatinib—KIT—endothelium—acquired immunodeficiency syndrome	0.000785	0.0103	CbGeAlD
Imatinib—CSF1R—blood plasma—acquired immunodeficiency syndrome	0.000768	0.0101	CbGeAlD
Imatinib—ABCA3—blood—acquired immunodeficiency syndrome	0.000765	0.0101	CbGeAlD
Imatinib—ABCA3—spinal cord—acquired immunodeficiency syndrome	0.000737	0.00969	CbGeAlD
Imatinib—ABCA3—vagina—acquired immunodeficiency syndrome	0.000709	0.00932	CbGeAlD
Imatinib—DDR1—blood—acquired immunodeficiency syndrome	0.000706	0.00928	CbGeAlD
Imatinib—KIT—blood plasma—acquired immunodeficiency syndrome	0.000697	0.00916	CbGeAlD
Imatinib—DDR1—spinal cord—acquired immunodeficiency syndrome	0.000681	0.00894	CbGeAlD
Imatinib—ABCA3—lung—acquired immunodeficiency syndrome	0.000671	0.00882	CbGeAlD
Imatinib—DDR1—vagina—acquired immunodeficiency syndrome	0.000655	0.00861	CbGeAlD
Imatinib—PIP4K2C—retina—acquired immunodeficiency syndrome	0.000652	0.00857	CbGeAlD
Imatinib—CA1—blood plasma—acquired immunodeficiency syndrome	0.000638	0.00838	CbGeAlD
Imatinib—ABCA3—nervous system—acquired immunodeficiency syndrome	0.000621	0.00817	CbGeAlD
Imatinib—DDR1—lung—acquired immunodeficiency syndrome	0.000619	0.00814	CbGeAlD
Imatinib—ABCA3—central nervous system—acquired immunodeficiency syndrome	0.000598	0.00786	CbGeAlD
Imatinib—HIPK4—brain—acquired immunodeficiency syndrome	0.00048	0.00631	CbGeAlD
Imatinib—CA7—digestive system—acquired immunodeficiency syndrome	0.000476	0.00626	CbGeAlD
Imatinib—ABCA3—brain—acquired immunodeficiency syndrome	0.000475	0.00624	CbGeAlD
Imatinib—ABL2—blood—acquired immunodeficiency syndrome	0.000461	0.00606	CbGeAlD
Imatinib—ABCA3—lymph node—acquired immunodeficiency syndrome	0.000459	0.00603	CbGeAlD
Imatinib—CYP2C19—blood plasma—acquired immunodeficiency syndrome	0.000451	0.00593	CbGeAlD
Imatinib—DDR1—brain—acquired immunodeficiency syndrome	0.000438	0.00576	CbGeAlD
Imatinib—PIP4K2C—blood—acquired immunodeficiency syndrome	0.000436	0.00573	CbGeAlD
Imatinib—ABL2—vagina—acquired immunodeficiency syndrome	0.000427	0.00561	CbGeAlD
Imatinib—DDR1—lymph node—acquired immunodeficiency syndrome	0.000424	0.00557	CbGeAlD
Imatinib—PIP4K2C—bone marrow—acquired immunodeficiency syndrome	0.000422	0.00554	CbGeAlD
Imatinib—PIP4K2C—spinal cord—acquired immunodeficiency syndrome	0.00042	0.00552	CbGeAlD
Imatinib—CA9—digestive system—acquired immunodeficiency syndrome	0.000418	0.0055	CbGeAlD
Imatinib—CA2—blood plasma—acquired immunodeficiency syndrome	0.000413	0.00543	CbGeAlD
Imatinib—PIP4K2C—vagina—acquired immunodeficiency syndrome	0.000404	0.00531	CbGeAlD
Imatinib—ABL2—lung—acquired immunodeficiency syndrome	0.000404	0.00531	CbGeAlD
Imatinib—CA3—bone marrow—acquired immunodeficiency syndrome	0.000403	0.00529	CbGeAlD
Imatinib—LCK—blood—acquired immunodeficiency syndrome	0.000387	0.00509	CbGeAlD
Imatinib—CA3—vagina—acquired immunodeficiency syndrome	0.000386	0.00507	CbGeAlD
Imatinib—PIP4K2C—lung—acquired immunodeficiency syndrome	0.000382	0.00502	CbGeAlD
Imatinib—LCK—bone marrow—acquired immunodeficiency syndrome	0.000374	0.00492	CbGeAlD
Imatinib—CSF1R—skin of body—acquired immunodeficiency syndrome	0.000369	0.00485	CbGeAlD
Imatinib—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.000368	0.00484	CbGeAlD
Imatinib—CA3—lung—acquired immunodeficiency syndrome	0.000365	0.0048	CbGeAlD
Imatinib—CA14—spinal cord—acquired immunodeficiency syndrome	0.000364	0.00479	CbGeAlD
Imatinib—PTGS1—endothelium—acquired immunodeficiency syndrome	0.000359	0.00472	CbGeAlD
Imatinib—LCK—vagina—acquired immunodeficiency syndrome	0.000359	0.00472	CbGeAlD
Imatinib—CYP3A5—blood plasma—acquired immunodeficiency syndrome	0.000355	0.00467	CbGeAlD
Imatinib—PIP4K2C—nervous system—acquired immunodeficiency syndrome	0.000354	0.00465	CbGeAlD
Imatinib—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.00035	0.00459	CbGeAlD
Imatinib—PIP4K2C—central nervous system—acquired immunodeficiency syndrome	0.000341	0.00448	CbGeAlD
Imatinib—PDGFRA—lymphoid tissue—acquired immunodeficiency syndrome	0.000339	0.00446	CbGeAlD
Imatinib—LCK—lung—acquired immunodeficiency syndrome	0.000339	0.00446	CbGeAlD
Imatinib—CA3—nervous system—acquired immunodeficiency syndrome	0.000338	0.00444	CbGeAlD
Imatinib—PDGFRA—digestive system—acquired immunodeficiency syndrome	0.000335	0.00441	CbGeAlD
Imatinib—KIT—skin of body—acquired immunodeficiency syndrome	0.000335	0.0044	CbGeAlD
Imatinib—ABL1—retina—acquired immunodeficiency syndrome	0.000332	0.00437	CbGeAlD
Imatinib—PDGFRB—skin of body—acquired immunodeficiency syndrome	0.000327	0.0043	CbGeAlD
Imatinib—CA3—central nervous system—acquired immunodeficiency syndrome	0.000325	0.00428	CbGeAlD
Imatinib—NQO2—blood—acquired immunodeficiency syndrome	0.00032	0.00421	CbGeAlD
Imatinib—PDGFRA—blood—acquired immunodeficiency syndrome	0.000319	0.0042	CbGeAlD
Imatinib—PTGS1—blood plasma—acquired immunodeficiency syndrome	0.000319	0.00419	CbGeAlD
Imatinib—SLC22A2—digestive system—acquired immunodeficiency syndrome	0.000318	0.00419	CbGeAlD
Imatinib—NQO2—bone marrow—acquired immunodeficiency syndrome	0.00031	0.00407	CbGeAlD
Imatinib—CA12—digestive system—acquired immunodeficiency syndrome	0.000309	0.00407	CbGeAlD
Imatinib—NQO2—spinal cord—acquired immunodeficiency syndrome	0.000309	0.00405	CbGeAlD
Imatinib—PDGFRA—spinal cord—acquired immunodeficiency syndrome	0.000308	0.00404	CbGeAlD
Imatinib—CSF1R—lymphoid tissue—acquired immunodeficiency syndrome	0.000299	0.00393	CbGeAlD
Imatinib—NQO2—vagina—acquired immunodeficiency syndrome	0.000297	0.0039	CbGeAlD
Imatinib—PDGFRA—vagina—acquired immunodeficiency syndrome	0.000296	0.00389	CbGeAlD
Imatinib—CSF1R—digestive system—acquired immunodeficiency syndrome	0.000295	0.00388	CbGeAlD
Imatinib—ABL1—skin of body—acquired immunodeficiency syndrome	0.000292	0.00383	CbGeAlD
Imatinib—ABL2—brain—acquired immunodeficiency syndrome	0.000286	0.00376	CbGeAlD
Imatinib—CA7—brain—acquired immunodeficiency syndrome	0.000282	0.0037	CbGeAlD
Imatinib—CSF1R—blood—acquired immunodeficiency syndrome	0.000281	0.0037	CbGeAlD
Imatinib—NQO2—lung—acquired immunodeficiency syndrome	0.000281	0.00369	CbGeAlD
Imatinib—PDGFRA—lung—acquired immunodeficiency syndrome	0.00028	0.00368	CbGeAlD
Imatinib—ABL2—lymph node—acquired immunodeficiency syndrome	0.000276	0.00363	CbGeAlD
Imatinib—CSF1R—bone marrow—acquired immunodeficiency syndrome	0.000272	0.00358	CbGeAlD
Imatinib—KIT—lymphoid tissue—acquired immunodeficiency syndrome	0.000271	0.00357	CbGeAlD
Imatinib—CSF1R—spinal cord—acquired immunodeficiency syndrome	0.000271	0.00356	CbGeAlD
Imatinib—PIP4K2C—brain—acquired immunodeficiency syndrome	0.000271	0.00356	CbGeAlD
Imatinib—SLC47A1—digestive system—acquired immunodeficiency syndrome	0.00027	0.00354	CbGeAlD
Imatinib—KIT—digestive system—acquired immunodeficiency syndrome	0.000268	0.00352	CbGeAlD
Imatinib—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000267	0.0035	CbGeAlD
Imatinib—PDGFRB—lymphoid tissue—acquired immunodeficiency syndrome	0.000265	0.00348	CbGeAlD
Imatinib—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000262	0.00345	CbGeAlD
Imatinib—PDGFRB—digestive system—acquired immunodeficiency syndrome	0.000262	0.00344	CbGeAlD
Imatinib—PIP4K2C—lymph node—acquired immunodeficiency syndrome	0.000261	0.00344	CbGeAlD
Imatinib—CSF1R—vagina—acquired immunodeficiency syndrome	0.000261	0.00343	CbGeAlD
Imatinib—NQO2—nervous system—acquired immunodeficiency syndrome	0.00026	0.00342	CbGeAlD
Imatinib—PDGFRA—nervous system—acquired immunodeficiency syndrome	0.000259	0.00341	CbGeAlD
Imatinib—CA12—lung—acquired immunodeficiency syndrome	0.000258	0.0034	CbGeAlD
Imatinib—CA3—brain—acquired immunodeficiency syndrome	0.000258	0.0034	CbGeAlD
Imatinib—SLC47A1—blood—acquired immunodeficiency syndrome	0.000257	0.00338	CbGeAlD
Imatinib—KIT—blood—acquired immunodeficiency syndrome	0.000255	0.00336	CbGeAlD
Imatinib—NQO2—central nervous system—acquired immunodeficiency syndrome	0.00025	0.00329	CbGeAlD
Imatinib—PDGFRA—central nervous system—acquired immunodeficiency syndrome	0.00025	0.00328	CbGeAlD
Imatinib—CA3—lymph node—acquired immunodeficiency syndrome	0.00025	0.00328	CbGeAlD
Imatinib—PDGFRB—blood—acquired immunodeficiency syndrome	0.000249	0.00328	CbGeAlD
Imatinib—CA1—lymphoid tissue—acquired immunodeficiency syndrome	0.000248	0.00326	CbGeAlD
Imatinib—SLC47A1—spinal cord—acquired immunodeficiency syndrome	0.000247	0.00325	CbGeAlD
Imatinib—KIT—bone marrow—acquired immunodeficiency syndrome	0.000247	0.00325	CbGeAlD
Imatinib—CSF1R—lung—acquired immunodeficiency syndrome	0.000247	0.00324	CbGeAlD
Imatinib—KIT—spinal cord—acquired immunodeficiency syndrome	0.000246	0.00323	CbGeAlD
Imatinib—CA1—digestive system—acquired immunodeficiency syndrome	0.000245	0.00322	CbGeAlD
Imatinib—PDGFRB—bone marrow—acquired immunodeficiency syndrome	0.000241	0.00317	CbGeAlD
Imatinib—PDGFRB—spinal cord—acquired immunodeficiency syndrome	0.00024	0.00316	CbGeAlD
Imatinib—CA12—nervous system—acquired immunodeficiency syndrome	0.000239	0.00315	CbGeAlD
Imatinib—SLC47A1—vagina—acquired immunodeficiency syndrome	0.000238	0.00313	CbGeAlD
Imatinib—KIT—vagina—acquired immunodeficiency syndrome	0.000237	0.00311	CbGeAlD
Imatinib—ABL1—lymphoid tissue—acquired immunodeficiency syndrome	0.000236	0.0031	CbGeAlD
Imatinib—CA14—brain—acquired immunodeficiency syndrome	0.000235	0.00308	CbGeAlD
Imatinib—ORM1—blood—acquired immunodeficiency syndrome	0.000234	0.00307	CbGeAlD
Imatinib—CA1—blood—acquired immunodeficiency syndrome	0.000234	0.00307	CbGeAlD
Imatinib—ABL1—digestive system—acquired immunodeficiency syndrome	0.000233	0.00307	CbGeAlD
Imatinib—LCK—lymph node—acquired immunodeficiency syndrome	0.000232	0.00305	CbGeAlD
Imatinib—PDGFRB—vagina—acquired immunodeficiency syndrome	0.000231	0.00304	CbGeAlD
Imatinib—CA12—central nervous system—acquired immunodeficiency syndrome	0.00023	0.00303	CbGeAlD
Imatinib—CSF1R—nervous system—acquired immunodeficiency syndrome	0.000228	0.003	CbGeAlD
Imatinib—ORM1—bone marrow—acquired immunodeficiency syndrome	0.000226	0.00298	CbGeAlD
Imatinib—CA2—retina—acquired immunodeficiency syndrome	0.000226	0.00297	CbGeAlD
Imatinib—CA1—bone marrow—acquired immunodeficiency syndrome	0.000226	0.00297	CbGeAlD
Imatinib—ORM1—spinal cord—acquired immunodeficiency syndrome	0.000225	0.00296	CbGeAlD
Imatinib—SLC47A1—lung—acquired immunodeficiency syndrome	0.000225	0.00296	CbGeAlD
Imatinib—CA1—spinal cord—acquired immunodeficiency syndrome	0.000225	0.00296	CbGeAlD
Imatinib—KIT—lung—acquired immunodeficiency syndrome	0.000224	0.00294	CbGeAlD
Imatinib—ABL1—blood—acquired immunodeficiency syndrome	0.000222	0.00292	CbGeAlD
Imatinib—CSF1R—central nervous system—acquired immunodeficiency syndrome	0.00022	0.00289	CbGeAlD
Imatinib—PDGFRB—lung—acquired immunodeficiency syndrome	0.000219	0.00287	CbGeAlD
Imatinib—ABL1—bone marrow—acquired immunodeficiency syndrome	0.000215	0.00283	CbGeAlD
Imatinib—SLC22A1—blood—acquired immunodeficiency syndrome	0.000214	0.00282	CbGeAlD
Imatinib—ABL1—spinal cord—acquired immunodeficiency syndrome	0.000214	0.00281	CbGeAlD
Imatinib—SLC47A1—nervous system—acquired immunodeficiency syndrome	0.000208	0.00274	CbGeAlD
Imatinib—KIT—nervous system—acquired immunodeficiency syndrome	0.000207	0.00272	CbGeAlD
Imatinib—ABL1—vagina—acquired immunodeficiency syndrome	0.000206	0.00271	CbGeAlD
Imatinib—ORM1—lung—acquired immunodeficiency syndrome	0.000205	0.0027	CbGeAlD
Imatinib—CA1—lung—acquired immunodeficiency syndrome	0.000205	0.00269	CbGeAlD
Imatinib—PDGFRB—nervous system—acquired immunodeficiency syndrome	0.000202	0.00266	CbGeAlD
Imatinib—SLC47A1—central nervous system—acquired immunodeficiency syndrome	0.000201	0.00264	CbGeAlD
Imatinib—KIT—central nervous system—acquired immunodeficiency syndrome	0.0002	0.00262	CbGeAlD
Imatinib—NQO2—brain—acquired immunodeficiency syndrome	0.000199	0.00261	CbGeAlD
Imatinib—SLC22A1—vagina—acquired immunodeficiency syndrome	0.000199	0.00261	CbGeAlD
Imatinib—CA2—skin of body—acquired immunodeficiency syndrome	0.000199	0.00261	CbGeAlD
Imatinib—PDGFRA—brain—acquired immunodeficiency syndrome	0.000198	0.0026	CbGeAlD
Imatinib—PDGFRB—central nervous system—acquired immunodeficiency syndrome	0.000195	0.00256	CbGeAlD
Imatinib—ABL1—lung—acquired immunodeficiency syndrome	0.000195	0.00256	CbGeAlD
Imatinib—NQO2—lymph node—acquired immunodeficiency syndrome	0.000192	0.00252	CbGeAlD
Imatinib—PDGFRA—lymph node—acquired immunodeficiency syndrome	0.000192	0.00252	CbGeAlD
Imatinib—ORM1—nervous system—acquired immunodeficiency syndrome	0.00019	0.0025	CbGeAlD
Imatinib—CA1—nervous system—acquired immunodeficiency syndrome	0.00019	0.00249	CbGeAlD
Imatinib—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000189	0.00248	CbGeAlD
Imatinib—CA12—brain—acquired immunodeficiency syndrome	0.000183	0.0024	CbGeAlD
Imatinib—ORM1—central nervous system—acquired immunodeficiency syndrome	0.000183	0.0024	CbGeAlD
Imatinib—CA1—central nervous system—acquired immunodeficiency syndrome	0.000183	0.0024	CbGeAlD
Imatinib—ABL1—nervous system—acquired immunodeficiency syndrome	0.00018	0.00237	CbGeAlD
Imatinib—CSF1R—brain—acquired immunodeficiency syndrome	0.000174	0.00229	CbGeAlD
Imatinib—SLC22A1—nervous system—acquired immunodeficiency syndrome	0.000174	0.00229	CbGeAlD
Imatinib—ABL1—central nervous system—acquired immunodeficiency syndrome	0.000174	0.00228	CbGeAlD
Imatinib—CYP2C19—digestive system—acquired immunodeficiency syndrome	0.000173	0.00228	CbGeAlD
Imatinib—CSF1R—lymph node—acquired immunodeficiency syndrome	0.000169	0.00222	CbGeAlD
Imatinib—SLC22A1—central nervous system—acquired immunodeficiency syndrome	0.000167	0.0022	CbGeAlD
Imatinib—CYP2C19—blood—acquired immunodeficiency syndrome	0.000165	0.00217	CbGeAlD
Imatinib—CA2—lymphoid tissue—acquired immunodeficiency syndrome	0.000161	0.00211	CbGeAlD
Imatinib—SLC47A1—brain—acquired immunodeficiency syndrome	0.000159	0.00209	CbGeAlD
Imatinib—CA2—digestive system—acquired immunodeficiency syndrome	0.000159	0.00209	CbGeAlD
Imatinib—KIT—brain—acquired immunodeficiency syndrome	0.000158	0.00208	CbGeAlD
Imatinib—PDGFRB—brain—acquired immunodeficiency syndrome	0.000155	0.00203	CbGeAlD
Imatinib—SLC47A1—lymph node—acquired immunodeficiency syndrome	0.000154	0.00202	CbGeAlD
Imatinib—PTGS1—skin of body—acquired immunodeficiency syndrome	0.000153	0.00202	CbGeAlD
Imatinib—CYP2C19—vagina—acquired immunodeficiency syndrome	0.000153	0.00201	CbGeAlD
Imatinib—KIT—lymph node—acquired immunodeficiency syndrome	0.000153	0.00201	CbGeAlD
Imatinib—CA2—blood—acquired immunodeficiency syndrome	0.000151	0.00199	CbGeAlD
Imatinib—PDGFRB—lymph node—acquired immunodeficiency syndrome	0.00015	0.00197	CbGeAlD
Imatinib—CA2—bone marrow—acquired immunodeficiency syndrome	0.000146	0.00192	CbGeAlD
Imatinib—CA2—spinal cord—acquired immunodeficiency syndrome	0.000146	0.00192	CbGeAlD
Imatinib—CA1—brain—acquired immunodeficiency syndrome	0.000145	0.0019	CbGeAlD
Imatinib—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.000142	0.00186	CbGeAlD
Imatinib—CA2—vagina—acquired immunodeficiency syndrome	0.00014	0.00184	CbGeAlD
Imatinib—ORM1—lymph node—acquired immunodeficiency syndrome	0.00014	0.00184	CbGeAlD
Imatinib—ABCG2—blood—acquired immunodeficiency syndrome	0.00014	0.00184	CbGeAlD
Imatinib—CA1—lymph node—acquired immunodeficiency syndrome	0.00014	0.00184	CbGeAlD
Imatinib—ABL1—brain—acquired immunodeficiency syndrome	0.000138	0.00181	CbGeAlD
Imatinib—CYP3A5—digestive system—acquired immunodeficiency syndrome	0.000137	0.0018	CbGeAlD
Imatinib—ABCG2—bone marrow—acquired immunodeficiency syndrome	0.000136	0.00178	CbGeAlD
Imatinib—ABCG2—spinal cord—acquired immunodeficiency syndrome	0.000135	0.00177	CbGeAlD
Imatinib—CYP1A2—blood—acquired immunodeficiency syndrome	0.000135	0.00177	CbGeAlD
Imatinib—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000134	0.00177	CbGeAlD
Imatinib—ABL1—lymph node—acquired immunodeficiency syndrome	0.000133	0.00175	CbGeAlD
Imatinib—SLC22A1—brain—acquired immunodeficiency syndrome	0.000133	0.00175	CbGeAlD
Imatinib—CA2—lung—acquired immunodeficiency syndrome	0.000133	0.00174	CbGeAlD
Imatinib—CYP3A5—blood—acquired immunodeficiency syndrome	0.00013	0.00171	CbGeAlD
Imatinib—ABCG2—vagina—acquired immunodeficiency syndrome	0.00013	0.00171	CbGeAlD
Imatinib—CYP2C9—blood—acquired immunodeficiency syndrome	0.000128	0.00168	CbGeAlD
Imatinib—ALB—brain—acquired immunodeficiency syndrome	0.000127	0.00167	CbGeAlD
Imatinib—ALB—lymph node—acquired immunodeficiency syndrome	0.000123	0.00162	CbGeAlD
Imatinib—ABCG2—lung—acquired immunodeficiency syndrome	0.000123	0.00162	CbGeAlD
Imatinib—CA2—nervous system—acquired immunodeficiency syndrome	0.000123	0.00161	CbGeAlD
Imatinib—PTGS1—digestive system—acquired immunodeficiency syndrome	0.000123	0.00161	CbGeAlD
Imatinib—CYP3A5—vagina—acquired immunodeficiency syndrome	0.000121	0.00159	CbGeAlD
Imatinib—CA2—central nervous system—acquired immunodeficiency syndrome	0.000118	0.00155	CbGeAlD
Imatinib—CYP1A2—lung—acquired immunodeficiency syndrome	0.000118	0.00155	CbGeAlD
Imatinib—PTGS1—blood—acquired immunodeficiency syndrome	0.000117	0.00154	CbGeAlD
Imatinib—CYP3A5—lung—acquired immunodeficiency syndrome	0.000114	0.0015	CbGeAlD
Imatinib—PTGS1—spinal cord—acquired immunodeficiency syndrome	0.000113	0.00148	CbGeAlD
Imatinib—PTGS1—vagina—acquired immunodeficiency syndrome	0.000108	0.00142	CbGeAlD
Imatinib—ABCB1—retina—acquired immunodeficiency syndrome	0.000103	0.00136	CbGeAlD
Imatinib—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000103	0.00135	CbGeAlD
Imatinib—PTGS1—lung—acquired immunodeficiency syndrome	0.000102	0.00135	CbGeAlD
Imatinib—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000101	0.00133	CbGeAlD
Imatinib—CYP3A4—blood—acquired immunodeficiency syndrome	9.77e-05	0.00128	CbGeAlD
Imatinib—CYP2D6—blood—acquired immunodeficiency syndrome	9.61e-05	0.00126	CbGeAlD
Imatinib—PTGS1—nervous system—acquired immunodeficiency syndrome	9.49e-05	0.00125	CbGeAlD
Imatinib—CA2—brain—acquired immunodeficiency syndrome	9.39e-05	0.00123	CbGeAlD
Imatinib—PTGS1—central nervous system—acquired immunodeficiency syndrome	9.14e-05	0.0012	CbGeAlD
Imatinib—CA2—lymph node—acquired immunodeficiency syndrome	9.08e-05	0.00119	CbGeAlD
Imatinib—ABCG2—brain—acquired immunodeficiency syndrome	8.7e-05	0.00114	CbGeAlD
Imatinib—ABCG2—lymph node—acquired immunodeficiency syndrome	8.4e-05	0.0011	CbGeAlD
Imatinib—CYP3A4—nervous system—acquired immunodeficiency syndrome	7.93e-05	0.00104	CbGeAlD
Imatinib—CYP2D6—nervous system—acquired immunodeficiency syndrome	7.8e-05	0.00103	CbGeAlD
Imatinib—CYP3A4—central nervous system—acquired immunodeficiency syndrome	7.63e-05	0.001	CbGeAlD
Imatinib—CYP2D6—central nervous system—acquired immunodeficiency syndrome	7.51e-05	0.000987	CbGeAlD
Imatinib—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	7.35e-05	0.000965	CbGeAlD
Imatinib—ABCB1—digestive system—acquired immunodeficiency syndrome	7.26e-05	0.000954	CbGeAlD
Imatinib—PTGS1—brain—acquired immunodeficiency syndrome	7.25e-05	0.000953	CbGeAlD
Imatinib—PTGS1—lymph node—acquired immunodeficiency syndrome	7.01e-05	0.000921	CbGeAlD
Imatinib—ABCB1—blood—acquired immunodeficiency syndrome	6.91e-05	0.000908	CbGeAlD
Imatinib—ABCB1—bone marrow—acquired immunodeficiency syndrome	6.69e-05	0.000879	CbGeAlD
Imatinib—ABCB1—spinal cord—acquired immunodeficiency syndrome	6.66e-05	0.000875	CbGeAlD
Imatinib—ABCB1—vagina—acquired immunodeficiency syndrome	6.41e-05	0.000842	CbGeAlD
Imatinib—ABCB1—lung—acquired immunodeficiency syndrome	6.06e-05	0.000796	CbGeAlD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	5.98e-05	0.000328	CcSEcCtD
Imatinib—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	5.96e-05	0.000327	CcSEcCtD
Imatinib—CYP2D6—brain—acquired immunodeficiency syndrome	5.96e-05	0.000784	CbGeAlD
Imatinib—Pruritus—Abacavir—acquired immunodeficiency syndrome	5.96e-05	0.000327	CcSEcCtD
Imatinib—Fatigue—Indinavir—acquired immunodeficiency syndrome	5.96e-05	0.000327	CcSEcCtD
Imatinib—Anorexia—Delavirdine—acquired immunodeficiency syndrome	5.95e-05	0.000327	CcSEcCtD
Imatinib—Discomfort—Ritonavir—acquired immunodeficiency syndrome	5.95e-05	0.000327	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	5.95e-05	0.000326	CcSEcCtD
Imatinib—Cough—Saquinavir—acquired immunodeficiency syndrome	5.94e-05	0.000326	CcSEcCtD
Imatinib—Angioedema—Lamivudine—acquired immunodeficiency syndrome	5.94e-05	0.000326	CcSEcCtD
Imatinib—Constipation—Indinavir—acquired immunodeficiency syndrome	5.91e-05	0.000324	CcSEcCtD
Imatinib—Pain—Indinavir—acquired immunodeficiency syndrome	5.91e-05	0.000324	CcSEcCtD
Imatinib—Insomnia—Efavirenz—acquired immunodeficiency syndrome	5.9e-05	0.000324	CcSEcCtD
Imatinib—Urticaria—Zidovudine—acquired immunodeficiency syndrome	5.9e-05	0.000324	CcSEcCtD
Imatinib—Convulsion—Saquinavir—acquired immunodeficiency syndrome	5.9e-05	0.000324	CcSEcCtD
Imatinib—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	5.89e-05	0.000323	CcSEcCtD
Imatinib—Hypertension—Saquinavir—acquired immunodeficiency syndrome	5.88e-05	0.000323	CcSEcCtD
Imatinib—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	5.87e-05	0.000322	CcSEcCtD
Imatinib—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	5.87e-05	0.000322	CcSEcCtD
Imatinib—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	5.87e-05	0.000322	CcSEcCtD
Imatinib—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	5.86e-05	0.000322	CcSEcCtD
Imatinib—Malaise—Lamivudine—acquired immunodeficiency syndrome	5.86e-05	0.000322	CcSEcCtD
Imatinib—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	5.85e-05	0.000321	CcSEcCtD
Imatinib—Nausea—Didanosine—acquired immunodeficiency syndrome	5.85e-05	0.000321	CcSEcCtD
Imatinib—Vertigo—Lamivudine—acquired immunodeficiency syndrome	5.84e-05	0.00032	CcSEcCtD
Imatinib—Hypotension—Delavirdine—acquired immunodeficiency syndrome	5.84e-05	0.00032	CcSEcCtD
Imatinib—Syncope—Lamivudine—acquired immunodeficiency syndrome	5.83e-05	0.00032	CcSEcCtD
Imatinib—Confusional state—Ritonavir—acquired immunodeficiency syndrome	5.82e-05	0.00032	CcSEcCtD
Imatinib—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	5.82e-05	0.000319	CcSEcCtD
Imatinib—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	5.82e-05	0.000319	CcSEcCtD
Imatinib—Somnolence—Efavirenz—acquired immunodeficiency syndrome	5.8e-05	0.000319	CcSEcCtD
Imatinib—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	5.8e-05	0.000318	CcSEcCtD
Imatinib—Myalgia—Saquinavir—acquired immunodeficiency syndrome	5.8e-05	0.000318	CcSEcCtD
Imatinib—Chest pain—Saquinavir—acquired immunodeficiency syndrome	5.8e-05	0.000318	CcSEcCtD
Imatinib—Anxiety—Saquinavir—acquired immunodeficiency syndrome	5.78e-05	0.000317	CcSEcCtD
Imatinib—Oedema—Ritonavir—acquired immunodeficiency syndrome	5.78e-05	0.000317	CcSEcCtD
Imatinib—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	5.76e-05	0.000316	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	5.76e-05	0.000316	CcSEcCtD
Imatinib—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	5.75e-05	0.000315	CcSEcCtD
Imatinib—Discomfort—Saquinavir—acquired immunodeficiency syndrome	5.73e-05	0.000314	CcSEcCtD
Imatinib—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	5.71e-05	0.000313	CcSEcCtD
Imatinib—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	5.69e-05	0.000312	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	5.69e-05	0.000312	CcSEcCtD
Imatinib—Shock—Ritonavir—acquired immunodeficiency syndrome	5.68e-05	0.000312	CcSEcCtD
Imatinib—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	5.67e-05	0.000311	CcSEcCtD
Imatinib—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	5.67e-05	0.000311	CcSEcCtD
Imatinib—Cough—Lamivudine—acquired immunodeficiency syndrome	5.67e-05	0.000311	CcSEcCtD
Imatinib—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	5.67e-05	0.000311	CcSEcCtD
Imatinib—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	5.66e-05	0.000311	CcSEcCtD
Imatinib—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	5.65e-05	0.00031	CcSEcCtD
Imatinib—Dizziness—Stavudine—acquired immunodeficiency syndrome	5.65e-05	0.00031	CcSEcCtD
Imatinib—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	5.65e-05	0.00031	CcSEcCtD
Imatinib—Insomnia—Delavirdine—acquired immunodeficiency syndrome	5.65e-05	0.00031	CcSEcCtD
Imatinib—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	5.64e-05	0.000309	CcSEcCtD
Imatinib—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	5.64e-05	0.000309	CcSEcCtD
Imatinib—Convulsion—Lamivudine—acquired immunodeficiency syndrome	5.63e-05	0.000309	CcSEcCtD
Imatinib—Vomiting—Nevirapine—acquired immunodeficiency syndrome	5.63e-05	0.000309	CcSEcCtD
Imatinib—Fatigue—Efavirenz—acquired immunodeficiency syndrome	5.63e-05	0.000309	CcSEcCtD
Imatinib—ABCB1—nervous system—acquired immunodeficiency syndrome	5.61e-05	0.000738	CbGeAlD
Imatinib—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	5.61e-05	0.000308	CcSEcCtD
Imatinib—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	5.61e-05	0.000308	CcSEcCtD
Imatinib—Confusional state—Saquinavir—acquired immunodeficiency syndrome	5.61e-05	0.000308	CcSEcCtD
Imatinib—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	5.58e-05	0.000306	CcSEcCtD
Imatinib—Pain—Efavirenz—acquired immunodeficiency syndrome	5.58e-05	0.000306	CcSEcCtD
Imatinib—Constipation—Efavirenz—acquired immunodeficiency syndrome	5.58e-05	0.000306	CcSEcCtD
Imatinib—Rash—Nevirapine—acquired immunodeficiency syndrome	5.58e-05	0.000306	CcSEcCtD
Imatinib—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	5.58e-05	0.000306	CcSEcCtD
Imatinib—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	5.57e-05	0.000306	CcSEcCtD
Imatinib—Dizziness—Abacavir—acquired immunodeficiency syndrome	5.57e-05	0.000306	CcSEcCtD
Imatinib—Oedema—Saquinavir—acquired immunodeficiency syndrome	5.56e-05	0.000305	CcSEcCtD
Imatinib—Somnolence—Delavirdine—acquired immunodeficiency syndrome	5.55e-05	0.000305	CcSEcCtD
Imatinib—Headache—Nevirapine—acquired immunodeficiency syndrome	5.55e-05	0.000304	CcSEcCtD
Imatinib—Myalgia—Lamivudine—acquired immunodeficiency syndrome	5.53e-05	0.000304	CcSEcCtD
Imatinib—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	5.53e-05	0.000304	CcSEcCtD
Imatinib—Chest pain—Lamivudine—acquired immunodeficiency syndrome	5.53e-05	0.000304	CcSEcCtD
Imatinib—Infection—Saquinavir—acquired immunodeficiency syndrome	5.52e-05	0.000303	CcSEcCtD
Imatinib—Anxiety—Lamivudine—acquired immunodeficiency syndrome	5.51e-05	0.000303	CcSEcCtD
Imatinib—Anorexia—Ritonavir—acquired immunodeficiency syndrome	5.51e-05	0.000302	CcSEcCtD
Imatinib—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	5.5e-05	0.000302	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	5.49e-05	0.000302	CcSEcCtD
Imatinib—Urticaria—Indinavir—acquired immunodeficiency syndrome	5.49e-05	0.000301	CcSEcCtD
Imatinib—Shock—Saquinavir—acquired immunodeficiency syndrome	5.47e-05	0.0003	CcSEcCtD
Imatinib—Discomfort—Lamivudine—acquired immunodeficiency syndrome	5.47e-05	0.0003	CcSEcCtD
Imatinib—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	5.46e-05	0.0003	CcSEcCtD
Imatinib—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	5.46e-05	0.0003	CcSEcCtD
Imatinib—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	5.45e-05	0.000299	CcSEcCtD
Imatinib—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	5.45e-05	0.000299	CcSEcCtD
Imatinib—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	5.44e-05	0.000299	CcSEcCtD
Imatinib—Vomiting—Stavudine—acquired immunodeficiency syndrome	5.43e-05	0.000298	CcSEcCtD
Imatinib—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	5.43e-05	0.000298	CcSEcCtD
Imatinib—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	5.41e-05	0.000297	CcSEcCtD
Imatinib—Rash—Nelfinavir—acquired immunodeficiency syndrome	5.41e-05	0.000297	CcSEcCtD
Imatinib—ABCB1—central nervous system—acquired immunodeficiency syndrome	5.4e-05	0.00071	CbGeAlD
Imatinib—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	5.4e-05	0.000296	CcSEcCtD
Imatinib—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	5.4e-05	0.000296	CcSEcCtD
Imatinib—Hypotension—Ritonavir—acquired immunodeficiency syndrome	5.4e-05	0.000296	CcSEcCtD
Imatinib—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	5.39e-05	0.000296	CcSEcCtD
Imatinib—Rash—Stavudine—acquired immunodeficiency syndrome	5.39e-05	0.000296	CcSEcCtD
Imatinib—Fatigue—Delavirdine—acquired immunodeficiency syndrome	5.38e-05	0.000296	CcSEcCtD
Imatinib—Dermatitis—Stavudine—acquired immunodeficiency syndrome	5.38e-05	0.000296	CcSEcCtD
Imatinib—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	5.38e-05	0.000295	CcSEcCtD
Imatinib—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	5.37e-05	0.000295	CcSEcCtD
Imatinib—Headache—Nelfinavir—acquired immunodeficiency syndrome	5.37e-05	0.000295	CcSEcCtD
Imatinib—Headache—Stavudine—acquired immunodeficiency syndrome	5.35e-05	0.000294	CcSEcCtD
Imatinib—Vomiting—Abacavir—acquired immunodeficiency syndrome	5.35e-05	0.000294	CcSEcCtD
Imatinib—Confusional state—Lamivudine—acquired immunodeficiency syndrome	5.35e-05	0.000293	CcSEcCtD
Imatinib—Pain—Delavirdine—acquired immunodeficiency syndrome	5.34e-05	0.000293	CcSEcCtD
Imatinib—Constipation—Delavirdine—acquired immunodeficiency syndrome	5.34e-05	0.000293	CcSEcCtD
Imatinib—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	5.34e-05	0.000293	CcSEcCtD
Imatinib—Asthenia—Zidovudine—acquired immunodeficiency syndrome	5.33e-05	0.000293	CcSEcCtD
Imatinib—Rash—Abacavir—acquired immunodeficiency syndrome	5.31e-05	0.000291	CcSEcCtD
Imatinib—Dermatitis—Abacavir—acquired immunodeficiency syndrome	5.3e-05	0.000291	CcSEcCtD
Imatinib—Oedema—Lamivudine—acquired immunodeficiency syndrome	5.3e-05	0.000291	CcSEcCtD
Imatinib—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	5.3e-05	0.000291	CcSEcCtD
Imatinib—Anorexia—Saquinavir—acquired immunodeficiency syndrome	5.3e-05	0.000291	CcSEcCtD
Imatinib—Headache—Abacavir—acquired immunodeficiency syndrome	5.27e-05	0.00029	CcSEcCtD
Imatinib—Infection—Lamivudine—acquired immunodeficiency syndrome	5.27e-05	0.000289	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	5.26e-05	0.000289	CcSEcCtD
Imatinib—Nausea—Nevirapine—acquired immunodeficiency syndrome	5.26e-05	0.000289	CcSEcCtD
Imatinib—Pruritus—Zidovudine—acquired immunodeficiency syndrome	5.26e-05	0.000288	CcSEcCtD
Imatinib—Insomnia—Ritonavir—acquired immunodeficiency syndrome	5.22e-05	0.000287	CcSEcCtD
Imatinib—Shock—Lamivudine—acquired immunodeficiency syndrome	5.22e-05	0.000286	CcSEcCtD
Imatinib—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	5.2e-05	0.000285	CcSEcCtD
Imatinib—Hypotension—Saquinavir—acquired immunodeficiency syndrome	5.19e-05	0.000285	CcSEcCtD
Imatinib—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	5.19e-05	0.000285	CcSEcCtD
Imatinib—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	5.19e-05	0.000285	CcSEcCtD
Imatinib—Urticaria—Efavirenz—acquired immunodeficiency syndrome	5.19e-05	0.000285	CcSEcCtD
Imatinib—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	5.16e-05	0.000283	CcSEcCtD
Imatinib—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	5.16e-05	0.000283	CcSEcCtD
Imatinib—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	5.15e-05	0.000283	CcSEcCtD
Imatinib—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	5.15e-05	0.000283	CcSEcCtD
Imatinib—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	5.15e-05	0.000282	CcSEcCtD
Imatinib—Somnolence—Ritonavir—acquired immunodeficiency syndrome	5.13e-05	0.000282	CcSEcCtD
Imatinib—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	5.13e-05	0.000281	CcSEcCtD
Imatinib—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	5.11e-05	0.00028	CcSEcCtD
Imatinib—Nausea—Nelfinavir—acquired immunodeficiency syndrome	5.09e-05	0.00028	CcSEcCtD
Imatinib—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	5.09e-05	0.000279	CcSEcCtD
Imatinib—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	5.08e-05	0.000279	CcSEcCtD
Imatinib—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	5.08e-05	0.000279	CcSEcCtD
Imatinib—Nausea—Stavudine—acquired immunodeficiency syndrome	5.08e-05	0.000279	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	5.06e-05	0.000278	CcSEcCtD
Imatinib—Anorexia—Lamivudine—acquired immunodeficiency syndrome	5.06e-05	0.000277	CcSEcCtD
Imatinib—Insomnia—Saquinavir—acquired immunodeficiency syndrome	5.03e-05	0.000276	CcSEcCtD
Imatinib—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	5.02e-05	0.000276	CcSEcCtD
Imatinib—Nausea—Abacavir—acquired immunodeficiency syndrome	5e-05	0.000275	CcSEcCtD
Imatinib—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	4.99e-05	0.000274	CcSEcCtD
Imatinib—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	4.99e-05	0.000274	CcSEcCtD
Imatinib—Fatigue—Ritonavir—acquired immunodeficiency syndrome	4.98e-05	0.000273	CcSEcCtD
Imatinib—Urticaria—Delavirdine—acquired immunodeficiency syndrome	4.96e-05	0.000272	CcSEcCtD
Imatinib—Asthenia—Indinavir—acquired immunodeficiency syndrome	4.96e-05	0.000272	CcSEcCtD
Imatinib—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	4.96e-05	0.000272	CcSEcCtD
Imatinib—Hypotension—Lamivudine—acquired immunodeficiency syndrome	4.96e-05	0.000272	CcSEcCtD
Imatinib—Somnolence—Saquinavir—acquired immunodeficiency syndrome	4.94e-05	0.000271	CcSEcCtD
Imatinib—Pain—Ritonavir—acquired immunodeficiency syndrome	4.94e-05	0.000271	CcSEcCtD
Imatinib—Constipation—Ritonavir—acquired immunodeficiency syndrome	4.94e-05	0.000271	CcSEcCtD
Imatinib—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	4.94e-05	0.000271	CcSEcCtD
Imatinib—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	4.94e-05	0.000271	CcSEcCtD
Imatinib—Dizziness—Zidovudine—acquired immunodeficiency syndrome	4.91e-05	0.00027	CcSEcCtD
Imatinib—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	4.89e-05	0.000269	CcSEcCtD
Imatinib—Pruritus—Indinavir—acquired immunodeficiency syndrome	4.89e-05	0.000268	CcSEcCtD
Imatinib—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	4.83e-05	0.000265	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	4.83e-05	0.000265	CcSEcCtD
Imatinib—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	4.81e-05	0.000264	CcSEcCtD
Imatinib—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	4.8e-05	0.000263	CcSEcCtD
Imatinib—Insomnia—Lamivudine—acquired immunodeficiency syndrome	4.8e-05	0.000263	CcSEcCtD
Imatinib—Fatigue—Saquinavir—acquired immunodeficiency syndrome	4.79e-05	0.000263	CcSEcCtD
Imatinib—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	4.76e-05	0.000261	CcSEcCtD
Imatinib—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	4.76e-05	0.000261	CcSEcCtD
Imatinib—Pain—Saquinavir—acquired immunodeficiency syndrome	4.75e-05	0.000261	CcSEcCtD
Imatinib—Constipation—Saquinavir—acquired immunodeficiency syndrome	4.75e-05	0.000261	CcSEcCtD
Imatinib—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	4.73e-05	0.00026	CcSEcCtD
Imatinib—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	4.73e-05	0.000259	CcSEcCtD
Imatinib—Vomiting—Zidovudine—acquired immunodeficiency syndrome	4.72e-05	0.000259	CcSEcCtD
Imatinib—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	4.72e-05	0.000259	CcSEcCtD
Imatinib—Somnolence—Lamivudine—acquired immunodeficiency syndrome	4.71e-05	0.000259	CcSEcCtD
Imatinib—Rash—Zidovudine—acquired immunodeficiency syndrome	4.68e-05	0.000257	CcSEcCtD
Imatinib—Asthenia—Efavirenz—acquired immunodeficiency syndrome	4.68e-05	0.000257	CcSEcCtD
Imatinib—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	4.68e-05	0.000257	CcSEcCtD
Imatinib—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	4.67e-05	0.000256	CcSEcCtD
Imatinib—Headache—Zidovudine—acquired immunodeficiency syndrome	4.65e-05	0.000255	CcSEcCtD
Imatinib—Pruritus—Efavirenz—acquired immunodeficiency syndrome	4.62e-05	0.000253	CcSEcCtD
Imatinib—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	4.61e-05	0.000253	CcSEcCtD
Imatinib—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	4.6e-05	0.000253	CcSEcCtD
Imatinib—Urticaria—Ritonavir—acquired immunodeficiency syndrome	4.59e-05	0.000252	CcSEcCtD
Imatinib—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	4.58e-05	0.000251	CcSEcCtD
Imatinib—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	4.58e-05	0.000251	CcSEcCtD
Imatinib—Fatigue—Lamivudine—acquired immunodeficiency syndrome	4.57e-05	0.000251	CcSEcCtD
Imatinib—Dizziness—Indinavir—acquired immunodeficiency syndrome	4.57e-05	0.000251	CcSEcCtD
Imatinib—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	4.57e-05	0.000251	CcSEcCtD
Imatinib—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	4.57e-05	0.000251	CcSEcCtD
Imatinib—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	4.55e-05	0.00025	CcSEcCtD
Imatinib—Pain—Lamivudine—acquired immunodeficiency syndrome	4.53e-05	0.000249	CcSEcCtD
Imatinib—Constipation—Lamivudine—acquired immunodeficiency syndrome	4.53e-05	0.000249	CcSEcCtD
Imatinib—Asthenia—Delavirdine—acquired immunodeficiency syndrome	4.48e-05	0.000246	CcSEcCtD
Imatinib—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	4.47e-05	0.000245	CcSEcCtD
Imatinib—Pruritus—Delavirdine—acquired immunodeficiency syndrome	4.42e-05	0.000243	CcSEcCtD
Imatinib—Urticaria—Saquinavir—acquired immunodeficiency syndrome	4.42e-05	0.000242	CcSEcCtD
Imatinib—Nausea—Zidovudine—acquired immunodeficiency syndrome	4.41e-05	0.000242	CcSEcCtD
Imatinib—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	4.39e-05	0.000241	CcSEcCtD
Imatinib—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	4.39e-05	0.000241	CcSEcCtD
Imatinib—Vomiting—Indinavir—acquired immunodeficiency syndrome	4.39e-05	0.000241	CcSEcCtD
Imatinib—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	4.37e-05	0.00024	CcSEcCtD
Imatinib—Rash—Indinavir—acquired immunodeficiency syndrome	4.36e-05	0.000239	CcSEcCtD
Imatinib—Dermatitis—Indinavir—acquired immunodeficiency syndrome	4.35e-05	0.000239	CcSEcCtD
Imatinib—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	4.34e-05	0.000238	CcSEcCtD
Imatinib—Headache—Indinavir—acquired immunodeficiency syndrome	4.33e-05	0.000238	CcSEcCtD
Imatinib—Dizziness—Efavirenz—acquired immunodeficiency syndrome	4.32e-05	0.000237	CcSEcCtD
Imatinib—ABCB1—brain—acquired immunodeficiency syndrome	4.29e-05	0.000564	CbGeAlD
Imatinib—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	4.27e-05	0.000235	CcSEcCtD
Imatinib—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	4.26e-05	0.000234	CcSEcCtD
Imatinib—Urticaria—Lamivudine—acquired immunodeficiency syndrome	4.21e-05	0.000231	CcSEcCtD
Imatinib—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	4.19e-05	0.00023	CcSEcCtD
Imatinib—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	4.19e-05	0.00023	CcSEcCtD
Imatinib—Vomiting—Efavirenz—acquired immunodeficiency syndrome	4.15e-05	0.000228	CcSEcCtD
Imatinib—ABCB1—lymph node—acquired immunodeficiency syndrome	4.14e-05	0.000545	CbGeAlD
Imatinib—Asthenia—Ritonavir—acquired immunodeficiency syndrome	4.14e-05	0.000227	CcSEcCtD
Imatinib—Dizziness—Delavirdine—acquired immunodeficiency syndrome	4.13e-05	0.000227	CcSEcCtD
Imatinib—Rash—Efavirenz—acquired immunodeficiency syndrome	4.12e-05	0.000226	CcSEcCtD
Imatinib—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	4.11e-05	0.000226	CcSEcCtD
Imatinib—Nausea—Indinavir—acquired immunodeficiency syndrome	4.1e-05	0.000225	CcSEcCtD
Imatinib—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	4.1e-05	0.000225	CcSEcCtD
Imatinib—Headache—Efavirenz—acquired immunodeficiency syndrome	4.09e-05	0.000224	CcSEcCtD
Imatinib—Pruritus—Ritonavir—acquired immunodeficiency syndrome	4.09e-05	0.000224	CcSEcCtD
Imatinib—Asthenia—Saquinavir—acquired immunodeficiency syndrome	3.99e-05	0.000219	CcSEcCtD
Imatinib—Vomiting—Delavirdine—acquired immunodeficiency syndrome	3.97e-05	0.000218	CcSEcCtD
Imatinib—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	3.95e-05	0.000217	CcSEcCtD
Imatinib—Rash—Delavirdine—acquired immunodeficiency syndrome	3.94e-05	0.000216	CcSEcCtD
Imatinib—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	3.93e-05	0.000216	CcSEcCtD
Imatinib—Pruritus—Saquinavir—acquired immunodeficiency syndrome	3.93e-05	0.000216	CcSEcCtD
Imatinib—Headache—Delavirdine—acquired immunodeficiency syndrome	3.91e-05	0.000215	CcSEcCtD
Imatinib—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	3.91e-05	0.000214	CcSEcCtD
Imatinib—Nausea—Efavirenz—acquired immunodeficiency syndrome	3.88e-05	0.000213	CcSEcCtD
Imatinib—Dizziness—Ritonavir—acquired immunodeficiency syndrome	3.82e-05	0.00021	CcSEcCtD
Imatinib—Asthenia—Lamivudine—acquired immunodeficiency syndrome	3.8e-05	0.000209	CcSEcCtD
Imatinib—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	3.8e-05	0.000209	CcSEcCtD
Imatinib—Pruritus—Lamivudine—acquired immunodeficiency syndrome	3.75e-05	0.000206	CcSEcCtD
Imatinib—Nausea—Delavirdine—acquired immunodeficiency syndrome	3.71e-05	0.000204	CcSEcCtD
Imatinib—Dizziness—Saquinavir—acquired immunodeficiency syndrome	3.68e-05	0.000202	CcSEcCtD
Imatinib—Vomiting—Ritonavir—acquired immunodeficiency syndrome	3.67e-05	0.000202	CcSEcCtD
Imatinib—Rash—Ritonavir—acquired immunodeficiency syndrome	3.64e-05	0.0002	CcSEcCtD
Imatinib—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	3.64e-05	0.0002	CcSEcCtD
Imatinib—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	3.63e-05	0.000199	CcSEcCtD
Imatinib—Headache—Ritonavir—acquired immunodeficiency syndrome	3.62e-05	0.000199	CcSEcCtD
Imatinib—Vomiting—Saquinavir—acquired immunodeficiency syndrome	3.53e-05	0.000194	CcSEcCtD
Imatinib—Dizziness—Lamivudine—acquired immunodeficiency syndrome	3.51e-05	0.000192	CcSEcCtD
Imatinib—Rash—Saquinavir—acquired immunodeficiency syndrome	3.51e-05	0.000192	CcSEcCtD
Imatinib—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	3.5e-05	0.000192	CcSEcCtD
Imatinib—Headache—Saquinavir—acquired immunodeficiency syndrome	3.48e-05	0.000191	CcSEcCtD
Imatinib—Nausea—Ritonavir—acquired immunodeficiency syndrome	3.43e-05	0.000188	CcSEcCtD
Imatinib—Vomiting—Lamivudine—acquired immunodeficiency syndrome	3.37e-05	0.000185	CcSEcCtD
Imatinib—Rash—Lamivudine—acquired immunodeficiency syndrome	3.34e-05	0.000184	CcSEcCtD
Imatinib—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	3.34e-05	0.000183	CcSEcCtD
Imatinib—Headache—Lamivudine—acquired immunodeficiency syndrome	3.32e-05	0.000182	CcSEcCtD
Imatinib—Nausea—Saquinavir—acquired immunodeficiency syndrome	3.3e-05	0.000181	CcSEcCtD
Imatinib—Nausea—Lamivudine—acquired immunodeficiency syndrome	3.15e-05	0.000173	CcSEcCtD
Imatinib—KIT—DAP12 interactions—IL6—acquired immunodeficiency syndrome	1.56e-05	0.000843	CbGpPWpGaD
Imatinib—KIT—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	1.56e-05	0.000843	CbGpPWpGaD
Imatinib—KIT—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	1.56e-05	0.000843	CbGpPWpGaD
Imatinib—KIT—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	1.54e-05	0.000835	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	1.54e-05	0.000831	CbGpPWpGaD
Imatinib—KIT—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	1.53e-05	0.000828	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CCR2—acquired immunodeficiency syndrome	1.53e-05	0.000825	CbGpPWpGaD
Imatinib—PDGFRB—Downstream signaling of activated FGFR—IL6—acquired immunodeficiency syndrome	1.53e-05	0.000825	CbGpPWpGaD
Imatinib—KIT—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	1.52e-05	0.000824	CbGpPWpGaD
Imatinib—LCK—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	1.52e-05	0.000822	CbGpPWpGaD
Imatinib—ABL1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.51e-05	0.000817	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by ERBB4—IL6—acquired immunodeficiency syndrome	1.5e-05	0.000812	CbGpPWpGaD
Imatinib—CA9—Cellular responses to stress—IL6—acquired immunodeficiency syndrome	1.48e-05	0.000803	CbGpPWpGaD
Imatinib—LCK—Hemostasis—CSF2—acquired immunodeficiency syndrome	1.48e-05	0.000802	CbGpPWpGaD
Imatinib—PDGFRA—DAP12 interactions—IL6—acquired immunodeficiency syndrome	1.48e-05	0.000798	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	1.48e-05	0.000798	CbGpPWpGaD
Imatinib—PDGFRA—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	1.48e-05	0.000798	CbGpPWpGaD
Imatinib—SLC22A1—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	1.47e-05	0.000795	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	1.46e-05	0.000791	CbGpPWpGaD
Imatinib—KIT—Immune System—IFNA1—acquired immunodeficiency syndrome	1.45e-05	0.000785	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	1.45e-05	0.000784	CbGpPWpGaD
Imatinib—NTRK1—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.45e-05	0.000784	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	1.44e-05	0.00078	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.44e-05	0.000778	CbGpPWpGaD
Imatinib—PDGFRB—Downstream signal transduction—IL6—acquired immunodeficiency syndrome	1.43e-05	0.000776	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	1.43e-05	0.000772	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.42e-05	0.000769	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by ERBB2—IL6—acquired immunodeficiency syndrome	1.42e-05	0.000768	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—IFNG—acquired immunodeficiency syndrome	1.41e-05	0.000765	CbGpPWpGaD
Imatinib—PDGFRB—DAP12 signaling—IL6—acquired immunodeficiency syndrome	1.41e-05	0.000764	CbGpPWpGaD
Imatinib—KIT—Immune System—CD79A—acquired immunodeficiency syndrome	1.41e-05	0.000762	CbGpPWpGaD
Imatinib—LCK—Immune System—MBL2—acquired immunodeficiency syndrome	1.41e-05	0.000761	CbGpPWpGaD
Imatinib—ALB—Folate Metabolism—IL6—acquired immunodeficiency syndrome	1.4e-05	0.000759	CbGpPWpGaD
Imatinib—KIT—Disease—CXCR4—acquired immunodeficiency syndrome	1.4e-05	0.000757	CbGpPWpGaD
Imatinib—CA14—Metabolism—ALB—acquired immunodeficiency syndrome	1.38e-05	0.000748	CbGpPWpGaD
Imatinib—ALB—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	1.38e-05	0.000747	CbGpPWpGaD
Imatinib—KIT—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	1.38e-05	0.000747	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CCR2—acquired immunodeficiency syndrome	1.37e-05	0.000743	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IFNA1—acquired immunodeficiency syndrome	1.37e-05	0.000743	CbGpPWpGaD
Imatinib—CA6—Metabolism—ALB—acquired immunodeficiency syndrome	1.35e-05	0.000728	CbGpPWpGaD
Imatinib—ALB—Metabolism—TAT—acquired immunodeficiency syndrome	1.34e-05	0.000726	CbGpPWpGaD
Imatinib—ABL1—Immune System—CCR2—acquired immunodeficiency syndrome	1.34e-05	0.000724	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.34e-05	0.000723	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.34e-05	0.000723	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CD79A—acquired immunodeficiency syndrome	1.33e-05	0.000721	CbGpPWpGaD
Imatinib—PDGFRB—DAP12 interactions—IL6—acquired immunodeficiency syndrome	1.33e-05	0.000719	CbGpPWpGaD
Imatinib—PDGFRB—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	1.33e-05	0.000719	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	1.33e-05	0.000719	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—AGPS—acquired immunodeficiency syndrome	1.33e-05	0.000717	CbGpPWpGaD
Imatinib—PDGFRA—Disease—CXCR4—acquired immunodeficiency syndrome	1.32e-05	0.000716	CbGpPWpGaD
Imatinib—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	1.32e-05	0.000714	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	1.32e-05	0.000712	CbGpPWpGaD
Imatinib—PDGFRA—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	1.31e-05	0.000707	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	1.31e-05	0.000706	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	1.3e-05	0.000703	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	1.3e-05	0.000701	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	1.28e-05	0.000694	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	1.28e-05	0.000693	CbGpPWpGaD
Imatinib—LCK—Signaling by SCF-KIT—IL6—acquired immunodeficiency syndrome	1.28e-05	0.000692	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.28e-05	0.00069	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.28e-05	0.00069	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—IL2—acquired immunodeficiency syndrome	1.26e-05	0.00068	CbGpPWpGaD
Imatinib—CA7—Metabolism—ALB—acquired immunodeficiency syndrome	1.26e-05	0.00068	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IFNA1—acquired immunodeficiency syndrome	1.24e-05	0.000669	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	1.23e-05	0.000667	CbGpPWpGaD
Imatinib—LCK—Downstream signaling of activated FGFR—IL6—acquired immunodeficiency syndrome	1.22e-05	0.000662	CbGpPWpGaD
Imatinib—ABL1—Immune System—IFNA1—acquired immunodeficiency syndrome	1.21e-05	0.000652	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—TAT—acquired immunodeficiency syndrome	1.2e-05	0.000652	CbGpPWpGaD
Imatinib—LCK—Signaling by ERBB4—IL6—acquired immunodeficiency syndrome	1.2e-05	0.000652	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CD79A—acquired immunodeficiency syndrome	1.2e-05	0.00065	CbGpPWpGaD
Imatinib—PDGFRB—Disease—CXCR4—acquired immunodeficiency syndrome	1.19e-05	0.000645	CbGpPWpGaD
Imatinib—PDGFRB—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	1.18e-05	0.000637	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	1.18e-05	0.000636	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—ALB—acquired immunodeficiency syndrome	1.17e-05	0.000634	CbGpPWpGaD
Imatinib—ABL1—Immune System—CD79A—acquired immunodeficiency syndrome	1.17e-05	0.000633	CbGpPWpGaD
Imatinib—CA12—Metabolism—ALB—acquired immunodeficiency syndrome	1.16e-05	0.00063	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.15e-05	0.000624	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.15e-05	0.000623	CbGpPWpGaD
Imatinib—LCK—Downstream signal transduction—IL6—acquired immunodeficiency syndrome	1.15e-05	0.000622	CbGpPWpGaD
Imatinib—KIT—Immune System—CD40LG—acquired immunodeficiency syndrome	1.15e-05	0.000621	CbGpPWpGaD
Imatinib—LCK—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	1.14e-05	0.000619	CbGpPWpGaD
Imatinib—ALB—Metabolism—AGPS—acquired immunodeficiency syndrome	1.14e-05	0.000617	CbGpPWpGaD
Imatinib—LCK—Signaling by ERBB2—IL6—acquired immunodeficiency syndrome	1.14e-05	0.000616	CbGpPWpGaD
Imatinib—KIT—Immune System—CSF2—acquired immunodeficiency syndrome	1.14e-05	0.000614	CbGpPWpGaD
Imatinib—KIT—Immune System—CD8A—acquired immunodeficiency syndrome	1.14e-05	0.000614	CbGpPWpGaD
Imatinib—LCK—DAP12 signaling—IL6—acquired immunodeficiency syndrome	1.13e-05	0.000613	CbGpPWpGaD
Imatinib—ALB—Hemostasis—IFNA1—acquired immunodeficiency syndrome	1.13e-05	0.000612	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.12e-05	0.000606	CbGpPWpGaD
Imatinib—ALB—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	1.12e-05	0.000603	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	1.11e-05	0.000599	CbGpPWpGaD
Imatinib—LCK—Immune System—CCR2—acquired immunodeficiency syndrome	1.1e-05	0.000597	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	1.1e-05	0.000594	CbGpPWpGaD
Imatinib—KIT—Immune System—HLA-B—acquired immunodeficiency syndrome	1.09e-05	0.000591	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.09e-05	0.00059	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CD40LG—acquired immunodeficiency syndrome	1.09e-05	0.000588	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.08e-05	0.000582	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CSF2—acquired immunodeficiency syndrome	1.07e-05	0.000581	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CD8A—acquired immunodeficiency syndrome	1.07e-05	0.000581	CbGpPWpGaD
Imatinib—LCK—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	1.07e-05	0.000577	CbGpPWpGaD
Imatinib—LCK—DAP12 interactions—IL6—acquired immunodeficiency syndrome	1.07e-05	0.000577	CbGpPWpGaD
Imatinib—LCK—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	1.07e-05	0.000577	CbGpPWpGaD
Imatinib—KIT—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.06e-05	0.000574	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.06e-05	0.000573	CbGpPWpGaD
Imatinib—LCK—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	1.06e-05	0.000572	CbGpPWpGaD
Imatinib—LCK—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	1.05e-05	0.000567	CbGpPWpGaD
Imatinib—LCK—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	1.04e-05	0.000564	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.04e-05	0.000564	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—HLA-B—acquired immunodeficiency syndrome	1.03e-05	0.000559	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—AGPS—acquired immunodeficiency syndrome	1.02e-05	0.000554	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.02e-05	0.000551	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.02e-05	0.00055	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1e-05	0.000544	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1e-05	0.000542	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	1e-05	0.000541	CbGpPWpGaD
Imatinib—LCK—Immune System—IFNA1—acquired immunodeficiency syndrome	9.93e-06	0.000537	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	9.86e-06	0.000534	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	9.83e-06	0.000531	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	9.8e-06	0.00053	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	9.8e-06	0.00053	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CD40LG—acquired immunodeficiency syndrome	9.79e-06	0.00053	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CD8A—acquired immunodeficiency syndrome	9.68e-06	0.000524	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CSF2—acquired immunodeficiency syndrome	9.68e-06	0.000524	CbGpPWpGaD
Imatinib—LCK—Hemostasis—ALB—acquired immunodeficiency syndrome	9.66e-06	0.000522	CbGpPWpGaD
Imatinib—LCK—Immune System—CD79A—acquired immunodeficiency syndrome	9.64e-06	0.000521	CbGpPWpGaD
Imatinib—KIT—Disease—CCR5—acquired immunodeficiency syndrome	9.59e-06	0.000519	CbGpPWpGaD
Imatinib—LCK—Disease—CXCR4—acquired immunodeficiency syndrome	9.57e-06	0.000518	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—CD4—acquired immunodeficiency syndrome	9.55e-06	0.000517	CbGpPWpGaD
Imatinib—ABL1—Immune System—CD40LG—acquired immunodeficiency syndrome	9.54e-06	0.000516	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—IL2—acquired immunodeficiency syndrome	9.51e-06	0.000514	CbGpPWpGaD
Imatinib—LCK—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	9.45e-06	0.000511	CbGpPWpGaD
Imatinib—ABL1—Immune System—CD8A—acquired immunodeficiency syndrome	9.44e-06	0.00051	CbGpPWpGaD
Imatinib—ABL1—Immune System—CSF2—acquired immunodeficiency syndrome	9.44e-06	0.00051	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	9.42e-06	0.00051	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	9.39e-06	0.000508	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	9.34e-06	0.000505	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—HLA-B—acquired immunodeficiency syndrome	9.31e-06	0.000504	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—CD4—acquired immunodeficiency syndrome	9.31e-06	0.000503	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	9.27e-06	0.000502	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	9.27e-06	0.000502	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	9.17e-06	0.000496	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.16e-06	0.000496	CbGpPWpGaD
Imatinib—ALB—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	9.08e-06	0.000491	CbGpPWpGaD
Imatinib—ABL1—Immune System—HLA-B—acquired immunodeficiency syndrome	9.08e-06	0.000491	CbGpPWpGaD
Imatinib—PDGFRA—Disease—CCR5—acquired immunodeficiency syndrome	9.08e-06	0.000491	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by NGF—IL6—acquired immunodeficiency syndrome	9.05e-06	0.00049	CbGpPWpGaD
Imatinib—CA2—Metabolism—ALB—acquired immunodeficiency syndrome	8.91e-06	0.000482	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	8.89e-06	0.000481	CbGpPWpGaD
Imatinib—ALB—Hemostasis—CSF2—acquired immunodeficiency syndrome	8.86e-06	0.000479	CbGpPWpGaD
Imatinib—CA1—Metabolism—ALB—acquired immunodeficiency syndrome	8.54e-06	0.000462	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	8.35e-06	0.000452	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	8.35e-06	0.000452	CbGpPWpGaD
Imatinib—PTGS1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	8.18e-06	0.000443	CbGpPWpGaD
Imatinib—PDGFRB—Disease—CCR5—acquired immunodeficiency syndrome	8.18e-06	0.000442	CbGpPWpGaD
Imatinib—ABCG2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	8.1e-06	0.000438	CbGpPWpGaD
Imatinib—SLC22A2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	8.02e-06	0.000434	CbGpPWpGaD
Imatinib—ABL1—Axon guidance—IL6—acquired immunodeficiency syndrome	7.98e-06	0.000432	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	7.98e-06	0.000432	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	7.88e-06	0.000427	CbGpPWpGaD
Imatinib—LCK—Immune System—CD40LG—acquired immunodeficiency syndrome	7.86e-06	0.000425	CbGpPWpGaD
Imatinib—LCK—Hemostasis—IL2—acquired immunodeficiency syndrome	7.83e-06	0.000424	CbGpPWpGaD
Imatinib—LCK—Immune System—CSF2—acquired immunodeficiency syndrome	7.77e-06	0.00042	CbGpPWpGaD
Imatinib—LCK—Immune System—CD8A—acquired immunodeficiency syndrome	7.77e-06	0.00042	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—CD4—acquired immunodeficiency syndrome	7.66e-06	0.000415	CbGpPWpGaD
Imatinib—CA9—Metabolism—ALB—acquired immunodeficiency syndrome	7.51e-06	0.000406	CbGpPWpGaD
Imatinib—LCK—Immune System—HLA-B—acquired immunodeficiency syndrome	7.47e-06	0.000404	CbGpPWpGaD
Imatinib—SLC22A1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	7.47e-06	0.000404	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.45e-06	0.000403	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	7.39e-06	0.0004	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	7.36e-06	0.000398	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.34e-06	0.000397	CbGpPWpGaD
Imatinib—LCK—Signaling by NGF—IL6—acquired immunodeficiency syndrome	7.27e-06	0.000393	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	7.25e-06	0.000392	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	7.13e-06	0.000386	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—TNF—acquired immunodeficiency syndrome	7.06e-06	0.000382	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.05e-06	0.000382	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.95e-06	0.000376	CbGpPWpGaD
Imatinib—KIT—Immune System—IFNG—acquired immunodeficiency syndrome	6.75e-06	0.000365	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.71e-06	0.000363	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	6.7e-06	0.000363	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	6.7e-06	0.000363	CbGpPWpGaD
Imatinib—LCK—Disease—CCR5—acquired immunodeficiency syndrome	6.56e-06	0.000355	CbGpPWpGaD
Imatinib—KIT—Immune System—CD4—acquired immunodeficiency syndrome	6.52e-06	0.000353	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	6.51e-06	0.000352	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IFNG—acquired immunodeficiency syndrome	6.39e-06	0.000346	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.36e-06	0.000344	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.36e-06	0.000344	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.26e-06	0.000339	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CD4—acquired immunodeficiency syndrome	6.17e-06	0.000334	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	6.16e-06	0.000333	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—IL6—acquired immunodeficiency syndrome	6.06e-06	0.000328	CbGpPWpGaD
Imatinib—KIT—Disease—CD4—acquired immunodeficiency syndrome	6.02e-06	0.000326	CbGpPWpGaD
Imatinib—KIT—Immune System—IL2—acquired immunodeficiency syndrome	6e-06	0.000325	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IFNG—acquired immunodeficiency syndrome	5.76e-06	0.000311	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—IL6—acquired immunodeficiency syndrome	5.73e-06	0.00031	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.73e-06	0.00031	CbGpPWpGaD
Imatinib—PDGFRA—Disease—CD4—acquired immunodeficiency syndrome	5.7e-06	0.000308	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—IL6—acquired immunodeficiency syndrome	5.7e-06	0.000308	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL2—acquired immunodeficiency syndrome	5.68e-06	0.000307	CbGpPWpGaD
Imatinib—ABL1—Immune System—IFNG—acquired immunodeficiency syndrome	5.61e-06	0.000304	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CD4—acquired immunodeficiency syndrome	5.56e-06	0.000301	CbGpPWpGaD
Imatinib—ABL1—Immune System—CD4—acquired immunodeficiency syndrome	5.42e-06	0.000293	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.29e-06	0.000286	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—IL6—acquired immunodeficiency syndrome	5.16e-06	0.000279	CbGpPWpGaD
Imatinib—PDGFRB—Disease—CD4—acquired immunodeficiency syndrome	5.13e-06	0.000278	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL2—acquired immunodeficiency syndrome	5.12e-06	0.000277	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.1e-06	0.000276	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—IL6—acquired immunodeficiency syndrome	5.03e-06	0.000272	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.02e-06	0.000272	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL2—acquired immunodeficiency syndrome	4.99e-06	0.00027	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	4.72e-06	0.000255	CbGpPWpGaD
Imatinib—ALB—Hemostasis—IL2—acquired immunodeficiency syndrome	4.68e-06	0.000253	CbGpPWpGaD
Imatinib—LCK—Immune System—IFNG—acquired immunodeficiency syndrome	4.62e-06	0.00025	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.6e-06	0.000249	CbGpPWpGaD
Imatinib—LCK—Immune System—CD4—acquired immunodeficiency syndrome	4.46e-06	0.000241	CbGpPWpGaD
Imatinib—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	4.38e-06	0.000237	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	4.3e-06	0.000233	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—IL6—acquired immunodeficiency syndrome	4.14e-06	0.000224	CbGpPWpGaD
Imatinib—LCK—Disease—CD4—acquired immunodeficiency syndrome	4.12e-06	0.000223	CbGpPWpGaD
Imatinib—LCK—Immune System—IL2—acquired immunodeficiency syndrome	4.11e-06	0.000222	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.88e-06	0.00021	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—ALB—acquired immunodeficiency syndrome	3.79e-06	0.000205	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—ALB—acquired immunodeficiency syndrome	3.76e-06	0.000203	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—ALB—acquired immunodeficiency syndrome	3.75e-06	0.000203	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	3.68e-06	0.000199	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.67e-06	0.000199	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—ALB—acquired immunodeficiency syndrome	3.64e-06	0.000197	CbGpPWpGaD
Imatinib—KIT—Immune System—IL6—acquired immunodeficiency syndrome	3.53e-06	0.000191	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—ALB—acquired immunodeficiency syndrome	3.5e-06	0.000189	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL6—acquired immunodeficiency syndrome	3.34e-06	0.000181	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.31e-06	0.000179	CbGpPWpGaD
Imatinib—KIT—Disease—IL6—acquired immunodeficiency syndrome	3.26e-06	0.000176	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.11e-06	0.000168	CbGpPWpGaD
Imatinib—PDGFRA—Disease—IL6—acquired immunodeficiency syndrome	3.08e-06	0.000167	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL6—acquired immunodeficiency syndrome	3.01e-06	0.000163	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL6—acquired immunodeficiency syndrome	2.93e-06	0.000159	CbGpPWpGaD
Imatinib—PDGFRB—Disease—IL6—acquired immunodeficiency syndrome	2.78e-06	0.00015	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—ALB—acquired immunodeficiency syndrome	2.72e-06	0.000147	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.65e-06	0.000144	CbGpPWpGaD
Imatinib—LCK—Immune System—IL6—acquired immunodeficiency syndrome	2.41e-06	0.000131	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.28e-06	0.000123	CbGpPWpGaD
Imatinib—LCK—Disease—IL6—acquired immunodeficiency syndrome	2.23e-06	0.000121	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.16e-06	0.000117	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ALB—acquired immunodeficiency syndrome	2.1e-06	0.000114	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	2.05e-06	0.000111	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.94e-06	0.000105	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	1.93e-06	0.000105	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	1.92e-06	0.000104	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	1.64e-06	8.86e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.56e-06	8.44e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	1.26e-06	6.83e-05	CbGpPWpGaD
